

# How to ensure a successful tablet coating formulation development by using polyvinyl alcohol and HPMC in combination with calcium carbonate as a titanium dioxide alternative

Anja-Nadine Knüttel, Almut von der Brelie, Thomas Kipping, Alessandra Ambruosi



## Purpose

- Recent ban of titanium dioxide (TiO<sub>2</sub>; E171) for the use in food and nutritional supplements (European Commission). The regulation includes a commitment to review the necessity of titanium dioxide as a white colorant in medicinal products<sup>1</sup>.
- It is challenging to find a suitable alternative for TiO<sub>2</sub> because of its high opacity.
- As an approved white drug colorant in the EU, calcium carbonate is of interest as a potential alternative to TiO<sub>2</sub> in the coating process.

## Objectives

- Evaluate a suitable alternative pigment to TiO<sub>2</sub> for tablet coating.
- Deep assessment of calcium carbonate in terms of its opacifying potential as well as the impact on required process conditions.
- Recommended formulations with a comparable covering effect need to be identified.

## Methods

Colored tablet cores were manufactured using a rotary tablet press (FETTE 1200i) at 74 rpm; compression force: 10 kN; height: 5.0 mm; tablet diameter: 11 mm; targeted tablet weight: 500 mg. A simplified core formulation with red iron oxide as pigment was used: 98.0% mannitol +0.5% iron oxide +1.5% magnesium stearate. The coating with Parateck® COAT EMPROVE® ESSENTIAL (Polyvinyl alcohol, MilliporeSigma) was performed using a rotating drum coater type LDCS from Vector Freund Corporation. To identify a relevant coloring of the core tablets, different concentrations of iron oxide were tested and determined by color measurements. The ratio of mannitol was adapted in respect of the amount of iron oxide to simulate a suitable coloring.



**Figure 1.** Pre-mixtures of mannitol with different amounts of iron oxide.

Color measurements were performed by using Konica Minolta Spectrophotometer CM-700d. At a level of 0.5% iron oxide a suitable coloration of tablet cores was achieved to simulate potential colored drug substances and to evaluate the covering properties of calcium carbonate in comparison to titanium dioxide.

## Results

Based on the results it was found that CaCO<sub>3</sub> represents a viable alternative to TiO<sub>2</sub> by increasing the solid content in the coating dispersion without any negative effect on the viscosity or feasibility of the coating process in general. Although the effectiveness and efficiency to TiO<sub>2</sub> is not directly comparable, the covering effect of CaCO<sub>3</sub> can be enhanced by adapting the solid content of CaCO<sub>3</sub>.

Ingredients	Solid content [%]	Sample/ Batch	Density [g/ml]	Dyn. Visc. [mPas · s]
Parateck® COAT (PVA)	10	Basis Coating solution	1.0135	38.28
PVA + 30%* CaCO <sub>3</sub> + ...	15	FC-002-22	1.0521	15.24
PVA + 40%* CaCO <sub>3</sub> + ...	20	FC-003-22	1.0940	20.52
PVA + 40%* TiO <sub>2</sub> + ...	20	FC-004-22	1.0984	33.78
HPMC + 30%* CaCO <sub>3</sub> + ...	15	FC-010-22	1.0515	60.94
HPMC + 40%* CaCO <sub>3</sub> + ...	20	FC-011-22	1.0710	79.25
			1.0743	80.24

**Table 1.** Characterization of different coating solutions at 25 °C; \*In relation to the total solid content in the coating dispersion; ingredients include 10% talcum and 20% plasticizer; the amount of polymer was adapted to the individual formulation.

## Coating liquid

It was observed that the addition of pigments can affect the viscosity of the spraying liquid.

Calcium carbonate has low influence on viscosity in comparison to basic coating solution whereas for titanium dioxide an increase of viscosity is observed. This effect is even more pronounced when using HPMC based polymers (see Table 1).

## Film coated tablets

### Trials with calcium carbonate


- Constant & homogenous coating process was achieved.
- Higher solid content and weight gain lead to a better covering of colored core tablets.
- Higher coating thickness is achieved at same process conditions compared to TiO<sub>2</sub> (see Figure 2).

### Trials with titanium dioxide


- Requires higher speed and more time for homogenization of coating suspension with 30% w/w solid content.
- Higher solid content leads to material settling in coating pipe and spray gun blocking tendency.
- Lower coating thickness (see Figure 2).

**Formulation with calcium carbonate**  
FC-003-22, 20% Solid in coating dispersion, 40% Calcium carbonate, 5% Weight gain

**Formulation with titanium dioxide**  
FC-004-22, 20% Solid in coating dispersion, 40% Titanium dioxide, 5% Weight gain



**Figure 2.** Individual SEM images of tablet surfaces (left) and cut tablet cores (right).



**Figure 3.** Visual images of tablet surfaces coated with PVA-based Parateck® COAT Excipient and calcium carbonate vs. titanium dioxide.


Sample	Nr.	Starting conditions			Sample	Nr.	Starting conditions		
		L*	a*	b*			L*	a*	b*
Mannitol [10.6 kN]	1	99.36	0.03	0.38	Tablet cores	1	76.60	14.12	7.70
	2	99.37	0.04	0.37		2	75.80	14.68	8.00
	3	99.44	0.01	0.33		3	72.89	16.50	9.19
	4	99.47	0.02	0.33		4	76.23	14.54	8.01
	5	99.46	0.02	0.35		5	73.16	16.57	9.28
Mannitol + 0.25% iron oxide [10.6 kN]	1	86.93	8.20	3.78	FC-001-22 (CaCO <sub>3</sub> )	1	73.66	16.62	11.54
	2	85.99	8.31	3.65		2	69.74	18.73	12.24
	3	86.72	7.97	3.55		3	72.49	17.27	11.75
	4	87.60	7.59	3.29		4	72.80	17.26	12.07
	5	87.40	7.63	3.39		5	73.05	16.95	11.55
Mannitol + 0.5% iron oxide [10.6 kN]	1	80.89	10.83	4.79	FC-002-22 (CaCO <sub>3</sub> )	1	73.71	14.74	8.77
	2	79.82	11.35	5.20		2	75.70	14.40	9.26
	3	80.65	11.15	5.43		3	74.61	14.19	8.54
	4	81.40	10.71	5.03		4	75.79	14.62	9.58
	5	79.11	11.86	5.62		5	74.35	14.33	8.54
Mannitol + 0.75% iron oxide [10.6 kN]	1	79.57	11.67	5.72	FC-003-22 (CaCO <sub>3</sub> )	1	80.03	9.89	6.12
	2	81.11	10.69	5.01		2	79.32	10.03	5.90
	3	80.50	10.94	4.85		3	80.40	9.63	6.06
	4	79.19	11.69	5.52		4	79.22	9.85	5.78
	5	79.05	11.65	5.59		5	79.43	9.33	5.46
Mannitol + 1.0% iron oxide [10.6 kN]	1	72.77	15.07	7.56	FC-004-22 (CaCO <sub>3</sub> )	1	95.03	0.04	-0.98
	2	72.61	14.58	6.65		2	94.43	0.10	-1.12
	3	72.61	15.16	7.70		3	94.10	0.27	-1.09
	4	75.34	13.13	6.14		4	94.60	0.15	-1.05
	5	73.93	14.56	7.28		5	94.70	0.02	-1.05
Mannitol + 1.0% iron oxide [10.6 kN]	1	72.77	15.07	7.56	FC-005-22 (CaCO <sub>3</sub> )	1	81.78	7.64	5.94
	2	72.61	14.58	6.65		2	80.81	8.48	5.87
	3	72.61	15.16	7.70		3	81.01	8.16	5.87
	4	75.34	13.13	6.14		4	79.52	8.79	5.62
	5	73.93	14.56	7.28		5	81.02	8.64	6.18
Mannitol + 1.0% iron oxide [10.6 kN]	1	72.77	15.07	7.56	FC-006-22 (CaCO <sub>3</sub> )	1	84.11	4.74	6.14
	2	72.61	14.58	6.65		2	84.51	4.21	6.38
	3	72.61	15.16	7.70		3	83.76	4.51	5.98
	4	75.34	13.13	6.14		4	83.59	5.03	5.90
	5	73.93	14.56	7.28		5	84.74	4.36	6.35

**Table 2.** Color measurements to identify the amount of iron oxide for core tablets (n=5).

**Table 3.** Color measurements of the film-coated tablets (n=5).

## Conclusions

- The replacement of titanium dioxide by calcium carbonate has an interesting potential for future coating applications. In combination with polyvinyl alcohol low viscosities of the spraying liquid can be maintained even at high solid contents which can enable a high process efficiency
- This effect can potentially balance the required weight gains required to achieve the targeted covering effect of the core tablet surface.
- It could be demonstrated that iron oxide can be integrated in core-tablets to simulate stronger colored drug substances. Color measurements confirm the tendency that with higher calcium carbonate content the red coloring (parameter a) is further reduced indicating a stronger covering effect caused by higher opacity which is also confirmed by increasing L values (see Figure 4).



**Figure 4.** L\*a\*b color space distribution of coated tablets.

## References

- Official Journal of the European Union L 11/1 (18 Jan 2022): Commission Regulation (EU) 2022/63 of 14 January 2022.

Contact details: [thomas.kipping@milliporesigma.com](mailto:thomas.kipping@milliporesigma.com)

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the Vibrant M, SAFC, Parateck and Emprove are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. Lit. No. MS\_PS11614EN 11/2022

**SAFC®**

Pharma & Biopharma Raw Material Solutions